Sector News

Novartis, Lilly-backed Cavion poaches Teva executive as R&D head

August 15, 2017
Life sciences

Spyridon “Spyros” Papapetropoulos has joined the ranks of small, neurological disease-focused biotech Cavion as EVP of research and development and CMO.

The Charlottesville, Virginia-based company has taken on Papapetropoulos from struggling Teva, where he was most recently VP of global specialty development, neurodegenerative diseases, movement disorders and clinical trial innovation.

He’s also managed neuroscience research and medical affairs programs at Pfizer, as well as held roles at Allergan and Biogen, and joins the growing ranks of former Big Pharma execs marching into biotech roles.

Papapetropoulos will now lead Cavion’s R&D ops, namely its therapies based on the company’s T-type calcium channel (Cav3) platform, which aims to restore the brain’s natural rhythms.

“Spyros joins the Cavion team at an exciting time. He is an experienced leader with a passion for conducting innovative trials that deliver new treatment options to patients with neurological diseases with limited treatment options,” said Cavion CEO and President Andrew Krouse.

He added that Papapetropoulos would also help boost Cavion’s presence in the Boston/Cambridge area.

Papapetropoulos added: “Cavion’s selective Cav3 modulating platform, which includes best-in-class clinical stage compounds, is expected to restore rhythmic neuronal firing in brain regions associated with a variety of chronic neurological diseases.

“I look forward to working closely with Cavion’s team to apply innovative but empathetic approaches to achieving clinical breakthroughs. Our end goal is to bring safe, effective and accessible treatments to people with chronic neurological diseases, quickly and efficiently.”

Back in January, Cavion got off a $26.1 million series A financing with Lilly Ventures, Novartis Venture Fund and Enso Ventures.

Cav3 works by mediating thalamocortical dysrhythmia, and is slated to work in a host of neurological diseases such as essential tremor, Parkinson’s disease, neuropathic pain, and epilepsy, as well as orphan neurodevelopmental and genetic disorders such as Angelman and Dravet syndromes.

Cavion says it is will working on a “robust” proof-of-concept phase 2 for its Cav3 inhibitor CX-8998 in essential tremor, the most common movement disorder, which has more than 10 million patients in the U.S.

The biotech has also been cosponsoring a phase 1 trial of mibefradil, combined with hypofractionated radiation therapy, for recurrent glioblastoma with the Yale University Comprehensive Cancer Center.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).